GlassScriptPhysician profile
Stephen Cashman
NPI 1003812462
$2,067.33
in general payments reported to CMS, 2019-2025
15 companies · $511 in 2025
The $511 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $235 · 2020: $77.59 · 2021: $245 · 2022: $308 · 2023: $293 · 2024: $398 · 2025: $511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,144 · Education: $57.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.77 |
| Education | $57.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $538.83 | 2019-2025 | Dupixent, Libtayo |
| Glaxosmithkline, LLC. | $426.18 | 2021-2025 | Nucala |
| Genzyme Corporation | $404.04 | 2019-2025 | |
| Stryker Corporation | $196.04 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $164.22 | 2022-2025 | Tezspire, Fasenra |
| Sanofi-Aventis U.S. LLC | $92.98 | 2021 | |
| Alk-Abello, INC | $60.42 | 2021-2023 | Odactra, Grastek, Ragwitek |
| Merck Sharp & Dohme LLC | $35.94 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $30.61 | 2023 | Ryaltris |
| Kaleo, INC. | $28.48 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $27.68 | 2023 | Seglentis |
| Aerin Medical INC. | $19.72 | 2024 | |
| Inspire Medical Systems, INC. | $15.48 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $13.48 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $13.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cashman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.